Article
Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF.
Pathology international - 1 May 2020
Seto Katsutoshi, Haneda Masataka, Masago Katsuhiro, Fujita Shiro, Kato Seiichi, Sasaki Eiichi, Hosoda Waki, Murakami Yoshiko, Kuroda Hiroaki, Horio Yoshitsugu, Hida Toyoaki, Okubo Kenichi, Yatabe Yasushi
Abstract excerpt
BRAF mutations are rare driver mutations in non-small cell lung cancer (NSCLC), accounting for 1%-2% of the driver mutations, and the mutation spectrum has a wide range in contrast to other tumors. While V600E is a dominant mutation in melanoma, more than half of the mutations in NSCLCs are non-V600E. However, treatment with dabrafenib plus trametinib targets the BRAF V600E mutation exclusively. Therefore,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.